Multiple myeloma (MM) is characterized by the clonal proliferation of malignant plasma cells and refractoriness to traditional therapies. It has been shown that exosomes are involved in modulating the progression and the metastasis of cancers through microRNAs (miRs). Ceramide is a type of sphingolipid; the ceramide pathway of exosomal secretion has been shown to affect the apoptosis of cancer cells. But the role of this pathway in MM cell function, exosome function and miR regulation remains unknown. In this study, we showed that C6 ceramide (an exogenous ceramide supplement, 1.25-40 µmol/L) dose-dependently inhibited the proliferation and promoted the apoptosis in human MM OPM2 cell line, which were associated with elevated caspase 3/9 and PARP cleavage. We also found that C6 ceramide (5-20 µmol/L) dose-dependently stimulated exosome secretion and increased exosomal levels of tumor-suppressive miRs (miR 202, miR 16, miR 29b and miR 15a). Of note, exosomes from C6 ceramide-treated OPM2 cells could influence the proliferation and apoptosis of the recipient OPM2 cells, which correlated with increased tumor-suppressive exosomal miRs. In contrast, GW4869 (a ceramide inhibitor, 5-20 µmol/L) exerted the opposite effects on the regulation of MM function, exosome secretion and miR levels in MM exosomes. However, exosomes from GW4869-treated OPM2 cells had no effect on these miRs and the survival of targeted OPM2 cells. Taken together, our findings reveal that the ceramide pathway modulates MM survival, probably directly via the caspase pathway and indirectly via exosomal miR mechanisms.
Introduction
Multiple myeloma (MM) is characterized by uncontrolled monoclonal plasma cell proliferation and is the second most common hematological malignancy. It accounts for nearly 20% of deaths related to hematological malignancy [1, 2] . MM has a low 5-year survival rate of approximately 40% and is frequently refractory to traditional therapies [3, 4] . As such, indepth investigation of the cell biology of MM is urgently needed in order to develop novel chemotherapeutic targets for MM.
Mounting evidence has shown that cell-released exosomes play an essential role in intercellular communication through the transfer of bioactive molecules such as proteins, mRNAs and microRNAs (miRs) [5, 6] . Extracellular exosomes are emerging as potential therapeutic strategies and diagnostic biomarkers for various diseases, including cardiovascular diseases, neurological disorders and cancers [5, [7] [8] [9] . Despite an incomplete understanding of the mechanisms of exosome secretion, ceramide (a type of sphingolipid) has been well characterized as regulating exosome secretion under both physiological and pathological conditions [10, 11] . Interestingly, ceramide has also been shown to regulate growth, proliferation and apoptosis in multiple cancers, such as leukemia, colon carcinoma and ovarian cancer [12] [13] [14] . Ceramide C6 (C6-cer), as an exogenous ceramide supplement, can significantly induce apoptosis in different cancer cell lines [15] [16] [17] . On the other hand, the ceramide inhibitor GW4869 can remarkably decrease exosome generation and can promote human hepatocellular cancer cell proliferation [18, 19] . These observations suggest that the ceramide pathway plays a pivotal role in exosome secretion and the functions of cancer cells. However, the role of the ceramide pathway in the cellular and exosomal functions of MM has not been explored.
Tumor-suppressive miRs have been suggested to be involved in regulating MM survival. It was previously reported that the over-expression of miR 29b induces apoptosis and caspase 3 activation in MM cells [20] and that miR 15a/16 can promote MM apoptosis by suppressing the expression of the anti-apoptosis protein Bcl-2 [21] . Moreover, miR 202 can inhibit proliferation and can induce apoptosis in MM cells via regulating B-cell activating factors (BAFF) [22] . Of note, exosomes are the means to transfer miRNAs from donor cells to recipient cells, representing a novel method of intercellular communication [23] . Moreover, the ceramide pathway has been shown to induce the apoptosis of metastatic prostate cancer cells by triggering the secretion of tumor-suppressive miRs [24] . However, whether the ceramide pathway regulates the cellular and exosomal miRs of MM remains unclear.
In this study, we examined the effects of the ceramide pathway on the cellular and exosomal functions of MM. For our mechanistic investigation, we analyzed the possible links between the caspase-dependent pathway and tumor-suppressive miRs (miR 202, miR 16, miR 29b and miR 15a).
Materials and methods

Cell culture
Multiple myeloma (OPM2 cell line) was generously gifted by Dr Feng-huang ZHAN (University of Iowa). Cells were cultured in RPMI-1640 medium (HyClone, USA) with 10% fetal bovine serum (FBS) (HyClone, USA) and maintained at 37 °C with 5% CO 2 and 95% humidity. GW4869 or C6-cer (Sigma, USA) was routinely stored at -80 °C as a 5 mmol/L stock suspension in DMSO. Immediately prior to use, the suspension was solubilized by the addition of phosphate-buffered saline (PBS) and diluted into a working solution. The suspension was completely mixed and warmed to 37 °C until clear.
MTT assay of cell proliferation OPM2 cells (4×10 4 cells/mL) were treated with different concentrations of C6-cer or GW4869 and seeded in 96 well plates. After 24 h of incubation, cell viability was assessed by adding 1.0 mg/mL of Thiazolyl Blue Tetrazolium Bromide (Sigma Aldrich, USA) to the medium. After 4 h of incubation, the plate was centrifuged and the supernatant was removed. The pellets were solubilized with 100 μL/well DMSO. The absorbance of the samples against a background control (medium alone) was measured at 570 nm with a microliter plate reader (BioTek Instruments, USA). All experiments were performed in five replicates.
Apoptosis detection by Hoechst 33342 staining A Hoechst 33342 staining kit (BD, USA) was used to detect cell apoptosis. Cells were treated with C6-cer or GW4869 for 24 h. Then, cells were harvested, washed, and resuspended in 1× binding buffer according to the protocol provided in the kit. In the next step, cells were stained with Hoechst 33342 at 1 mg/mL for 15 min. Then, cells were washed with PBS twice and imaged under a fluorescence microscope.
Exosome isolation, detection and quantification Collection Exosomes were prepared from culture supernatants of OPM2 cells by differential centrifugations. Briefly, the cell medium was first collected and centrifuged at 300×g for 15 min, followed by centrifugation at 2000×g for 30 min to remove cells and cell debris. The cell-free culture medium was centrifuged at 20 000×g for 70 min and then ultracentrifuged at 170 000×g for 1.5 h to pellet the exosomes. The pelleted exosomes were resuspended with 20 nm filtered PBS (Whatman, USA).
Particle size and concentration analysis
Exosomes were resuspended in PBS, and the particle size and concentration were measured by using the Nanoparticle Tracking Analysis System 300 (NTA300, Malvern Instruments, UK). The NTA300 method has been recognized as an easy-touse, rapid and reproducible platform for exosome characterization [8] . In this study, diluted suspensions containing exosomes were loaded into the sample chamber. The light scatter mode of the tracking system used camera filter 1. Three videos of typically 30 s in duration were taken, with a frame rate of 30 frames per second. Data were analyzed by NTA 3.0 software (Malvern Instruments, USA), which was optimized to first identify and then to track each particle on a frame-byframe basis [8] .
Immunofluorescence staining
To identify the efficiency of exosome uptake, exosomes were labeled with PKH26 (Invitrogen, USA). Briefly, 30 μg of exosomes were re-suspended in 1 mL of Diluent C. Then, 4 μL of PKH26 were mixed with Diluent C prior to staining. The PKH26 suspension was mixed with the exosome suspension and incubated for 4 min, and protected from light. The staining reaction was stopped by the addition of an equal volume of 1% BSA and centrifuged at 170 000×g for 90 min at 4 °C. Then, pelleted exosomes were washed with PBS and centrifuged at 170 000×g for 90 min at 4 °C. The exosomes were suspended in 200 μL of supplemented RMPI-1640 medium and cultured with a confluent layer of OPM2 cells. Following co-incubation for 24 h, OPM2 cells were washed with PBS, stained with DAPI for 5 min, washed with PBS and fixed with 4% formaldehyde. Images of exosome uptake by OPM2 cells were acquired with an LSM710 laser scanning microscope (Carl Zeiss, Germany).
Protein extraction and western blot analysis
Whole-cell lysates and total exosomal proteins were prepared using RIPA buffer (50 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate). We electrophoretically separated 50 µg total protein on a 4%-12% SDS-acrylamide gel (Thermo Fisher Scientific, USA). Western blot analyses were performed with the following primary antibodies: anti-β-actin, anti-caspase 3, anti- RNA extraction and quantitative real-time PCR of miRs Total RNA was isolated using Trizol Reagent (Invitrogen, USA) according to the manufacturer's instructions. The purified RNA was subjected to reverse transcription reactions using the PrimeScript TM RT reagent kit (Takara, Japan). Quantitative real-time PCR (qRT-PCR) with SYBR Premix Ex Taq II Mix (Takara, Japan) was used to evaluate transcript levels; U6 was used as an internal control. All of the primer sequences are reported in Supplementary Table S1 . qRT-PCR assays were performed in the StepONEPlus Real-Time PCR system (Thermo Fisher Scientific, USA) and the relative expression was calculated using the comparative 2 −ΔΔCt method.
Statistical analysis
Statistical significance was calculated in Microsoft Excel using Student's t-test (one-sided) or ANOVA, as appropriate. The generated data displayed a normal distribution with similar variance, and analysis was performed assuming equal variance.
Results
The effect of the ceramide pathway on MM proliferation To determine the effect of the ceramide pathway on MM proliferation, OPM2 cells were treated with C6-cer or GW4869 at increasing concentrations (0, 1.25, 2.5, 5, 10, 20, 40 µmol/L) for 24 h and then proliferation was assessed with the MTT assay. As shown in Figure 1A , the proliferation of OPM2 cells was dose-dependently inhibited by C6-cer. By contrast, the cell proliferation rate was increased after GW4869 treatment ( Figure 1B) . The inhibition of cell proliferation was only significant when the concentration of GW4869 was 40 µmol/L or higher.
The effect of the ceramide pathway on MM apoptosis and the caspase pathway MM cell apoptosis in this study was evaluated by Hoechst 33342 staining assay (Figure 2A ). The apoptosis of MM cells was increased after C6-cer treatment (20 µmol/L) compared with controls (20.5%±1.72% vs 3.7%±1.54%, P<0.05; n=3, Figure 2B ). There was no significant difference in MM apoptosis following treatment with GW4869 (20 µmol/L). To explore the potential mechanism underlying the effect of the ceramide pathway on MM apoptosis, we assessed the expression levels of caspase 3/9, PARP and their cleaved forms ( Figure 2C ). There was no change in the total expression of caspase 3/9 or PARP. However, cleaved caspase 3/9 and PARP were significantly increased after C6-cer treatment ( Figure 2D ). These results indicated that the activation of the ceramide pathway promotes MM apoptosis, probably though the caspase pathway.
The effect of the ceramide pathway on exosome release from MM cells To examine the effects of the ceramide pathway on exosome release from MM cells, OPM2 cells were treated with C6-cer or GW4869 separately at increasing concentrations (0, 5.0, 10, 20 µmol/L). Then, the size and concentration were analyzed using the NTA 300. The size of OPM2 exosomes derived from C6-cer or GW4869 treatment mainly distributed from 40 nm to 200 nm ( Figure 3A, 3C ). C6-cer dose-dependently increased the number of exosomes released. The release of exosomes was increased nearly five-fold at the concentration of 20 µmol/L compared with controls ( Figure 3B ). By contrast, GW4869 gradually decreased exosome secretion by approximately 80% at a concentration of 20 µmol/L ( Figure 3D ). 
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Acta Pharmacologica Sinica changes were found in the miR levels in MM cells and exosomes following treatment with GW4869 ( Figure 4E-4H ).
The effect of the ceramide pathway on exosome functions and the miR levels of targeted MM cells We isolated MM exosomes after treatment with C6-cer (exosomes C6-cer ) or GW4869 (exosomes GW4869 ) using differential centrifugation. As shown in Figure 5A , Western blot analysis showed that the isolated MM exosomes were rich in CD63 and lacked Annexin V. The efficiency of exosome uptake was confirmed 24 h later using the PKH26 stain (Supplementary Figure S1) . After protein quantification, OPM2 cells were treated with 80 µg/mL exosomes C6-cer or exosomes GW4869 for 48 h. The results showed that the proliferation of OPM2 cells was significantly inhibited by exosomes C6-cer treatment ( Figure   5A ) in a time-dependent manner. In addition, exosomes C6-cer increased the apoptosis of MM cells (3.2%±1.3% vs 9.1%±1.9%, P<0.05; n=3). However, exosomes C6-cer had no effect on the expression of cleaved caspase 3/9 or PARP. Of note, the levels of these tumor-suppressive miRs were significantly altered in exosomes C6-cer treated MM cells. As shown in Figure 5 , exosomes GW4869 had no effect on cell proliferation, apoptosis or the miR concentrations of the recipient MM cells.
Discussion
In the present study, we demonstrated that the ceramide pathway can affect MM cells at several functional levels, including proliferation, apoptosis and exosomal, and revealed that these effects of the ceramide pathway are associated with the caspase pathway and several tumor-suppressive miRs, including 
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Acta Pharmacologica Sinica miR 146a, miR 29b, miR 15a and miR 16 ( Figure 6 ). Increasing evidence suggests that the ceramide pathway plays a crucial role in the proliferation and apoptosis of different cancer cells, such as colon carcinoma [25] , ovarian [14] and breast cancer [15] . In this study, the roles of the ceramide pathway in the proliferation and apoptosis of MM cells were determined by using C6-cer and GW4869 to modulate the activity of this pathway, as previously reported [15, 16, 26] . We found that C6-cer dose-dependently (1.25-40 µmol/L) inhibited MM proliferation (5%-80%), whereas GW4869 promoted proliferation (1-to 2-fold) in the same concentration range. These results are consistent with previous reports showing the effects of C6-cer and GW4869 on the proliferation of breast cancer cells [26, 27] . In addition, we found that C6-cer increased the apoptotic ratio of MM cells, which is similar to a previous study that demonstrated that C6-cer activates caspase-dependent apoptotic death in melanoma cells [28] . For the mechanistic analysis, we measured the levels of caspase 3/9 and PARP cleavage in MM cells. We found that C6-cer increased the expression of caspase 3/9 and PARP cleavage. However, we did not detect any significant effect of GW4869 on MM apoptosis. The failure of GW4869 to influence MM apoptosis is explainable as we did not observe any changes in the expression of caspase 3/9 or PARP cleavage. On the other hand, MM cells had a low basal apoptotic rate (approximately 4%) and low levels of caspase 3/9 and PARP cleavage, which could mask the effects of GW4869. Therefore, our data suggest that the ceramide pathway can modulate MM proliferation and apoptosis, probably through the mitochondrial caspase pathway. The ceramide pathway has also been demonstrated to participate in the modulation of exosome release in several cancer cells, including breast cancer [15] and prostate cancer [24] . However, whether it regulates the release of MM exosomes remains unknown. In this study, we showed that the activa- [24] . Previous studies have shown that miR 29b, miR 15a/16 and miR 202 are involved in MM proliferation and apoptosis [20, 21, 29] . Therefore, we also examined the effect of the ceramide pathway on the cellular and exosomal levels of these tumor-suppressive miRs. Our data showed that the activation of the ceramide pathway decreased the levels of these miRs in MM cells, but increased their levels in MM exosomes. On the other hand, inhibition of the ceramide pathway had contrasting effects. Our results suggest that the ceramide pathway plays an important role in the control of these miR levels in MM cells and exosomes. Of note, the alterations in intracellular miRs induced by C6-cer/ GW4869 could not explain the changes in MM function (proliferation and apoptosis). This discrepancy might be explained by the fact that C6-cer/GW4869 affects other pathways that overwhelm the effects of changes in tumor-suppressive miRs. Indeed, we discovered that C6-cer activated the caspase pathway in MM cells with upregulated caspase 3/9 and PARP cleavage by 4-fold. However, whether C6-cer induced cell apoptosis and exosome secretion are dependent on the caspase pathway requires further confirmation with a caspase inhibitor.
Cancer cell-derived exosomes have "paracrine" functions by communicating with surrounding cells through the transfer of bioactive molecules (miRs, mRNAs and proteins), which implicates exosomes in the proliferation and apoptosis of cancer cells [23, 30] . A previous study showed that MM exosomes could stimulate the secretion of cytokines from stromal cells to favor MM cell growth and migration [31] . However, it is unclear whether MM exosomes could perform these "paracrine" effects on neighboring MM cells. We isolated MM exosomes after separate C6-cer and GW4869 treatment, defined as exosomes C6-cer and exosomes GW4869 , to determine their "paracrine" effects on untreated MM cells. Our results showed that exosomes C6-cer inhibited proliferation and increased apoptosis in MM cells. To better understand the mechanism, we focused on caspase 3/9 and PARP, as well as these miRs. Interestingly, we did not detect any changes in cleaved caspase 3/9 and PARP, suggesting that the caspase pathway was not responsible for the effects of exosomes C6-cer in recipient MM cells. However, we found that exosomes C6-cer increased the levels of miR 202, miR 29b, miR 15a and miR 16 in treated MM cells. Therefore, a possible explanation for the function of exosomes C6-cer might be related to the increased levels of these tumor-suppressive miRs in exosomes C6-cer treated MM cells, although their downstream effectors, such as Bcl-2 and Mcl-1, remain to be elucidated. In addition, we found that exosomes GW4869 had no effect on the proliferation and apoptosis of recipient MM cells. A reasonable explanation for this finding is that the levels of miRs are unchanged in exosomes GW4869 treated MM cells as exosomes GW4869 have very low levels of these miRs. Moreover, in agreement with our observation that GW4869 had no effect on the caspase pathway of MM, exosomes GW4869 did not affect this pathway in exosomes GW4869 treated MM cells. Taken together, our data indicate that exosomes C6-cer inhibits proliferation and induces apoptosis in MM cells, probably by regulating these tumor-suppressive miRs in the targeted MM cells.
In conclusion, we identified important roles for the ceramide pathway in the proliferation, apoptosis and exosome functions of MM cells. Of note, the ceramide pathway modulates MM apoptosis, presumably by regulating the caspase-dependent pathway. Exosomes related to the ceramide pathway activated in MM cells inhibit proliferation and increase apoptosis in recipient MM cells, which correlated with the increased levels of exosomal miR 202, miR 29b, miR 15a and miR 16 . This study provides a novel understanding of MM biology that will have significant implications for the development of novel therapeutic and biomarker strategies.
